Welcome to our dedicated page for Allakos news (Ticker: ALLK), a resource for investors and traders seeking the latest updates and insights on Allakos stock.
The Allakos Inc. (ALLK) news page on Stock Titan aggregates company-issued updates and market-moving announcements for this clinical stage biotechnology firm. Allakos describes itself as a biotechnology company developing therapeutics that target immunomodulatory receptors on immune effector cells involved in allergy, inflammatory and proliferative diseases, with a particular focus on mast cell-driven conditions.
News items for Allakos commonly cover clinical trial milestones, such as Phase 1 single and multiple ascending dose studies of AK006 in healthy volunteers and chronic spontaneous urticaria (CSU) patients, as well as topline results from these trials. Releases have detailed safety, pharmacokinetics, pharmacodynamics, and Siglec-6 receptor occupancy data for AK006, along with exploratory efficacy outcomes in CSU.
Investors and followers can also find business updates and financial results, where Allakos reports research and development expenses, general and administrative costs, restructuring charges, cash, cash equivalents and investments, and the financial impact of halting specific development programs. These updates often include commentary on restructuring activities and cash outlook.
Another important category of news relates to strategic and corporate actions. Allakos has announced the discontinuation of AK006 development in CSU following lack of therapeutic activity in a Phase 1 cohort, significant workforce reductions, exploration of strategic alternatives, and a definitive merger agreement under which Concentra Biosciences, LLC will acquire Allakos through a tender offer and merger, subject to closing conditions.
In addition, Allakos issues scientific and conference communications, including preclinical data presentations on AK006’s mechanism of action, mast cell inhibition, and MRGPRX2-mediated mast cell activation in inflammatory skin diseases. Bookmark this page to review historical and ongoing disclosures that shape the narrative around ALLK’s clinical programs, restructuring steps, and acquisition process.
Allakos Inc. (Nasdaq: ALLK) reported significant findings from a study that indicates eosinophilic gastritis (EG) and eosinophilic duodenitis (EoD) are underdiagnosed in patients with chronic gastrointestinal symptoms. The study showed that 45% of symptomatic patients biopsied met the histologic criteria for these diseases. A total of 556 patients were screened, with 405 meeting symptom criteria for biopsy. The results suggest a potential market opportunity for lirentelimab (AK002), currently in clinical trials. A conference call is scheduled for today at 8:00 am ET.
Allakos Inc. (Nasdaq: ALLK) published Phase 2 study results of lirentelimab (AK002) in eosinophilic gastritis and duodenitis, revealing statistically significant improvements over placebo on primary and secondary endpoints. Key findings included reduced gastrointestinal tissue eosinophil counts and enhanced patient-reported symptoms. Lirentelimab has orphan drug designation for these conditions, addressing severe inflammatory diseases lacking approved treatments. The positive peer-reviewed publication in the New England Journal of Medicine bolsters the potential market impact for lirentelimab.
Allakos Inc. (Nasdaq: ALLK) is advancing its clinical studies for antolimab (AK002) targeting eosinophilic diseases. A Phase 3 study for eosinophilic gastritis and/or duodenitis is enrolling 160 patients, while a Phase 2/3 study for eosinophilic esophagitis aims to recruit 300 patients. Top-line results from both studies are anticipated in the second half of 2021. The company has orphan drug designation for antolimab in these conditions, which are characterized by severe inflammation and have no approved treatments, underscoring a significant unmet medical need.
Allakos (Nasdaq: ALLK) announced that two of its oral abstract presentations will be featured at the upcoming EAACI Annual Congress, scheduled for June 6-8, 2020. The presentations will cover the effects of antolimab (AK002) on eosinophil and mast cell-related diseases. The first presentation discusses how a Siglec-8 antibody reduces inflammation, while the second examines the treatment of severe allergic conjunctivitis, highlighting improvements in ocular signs and comorbid conditions. Slides from the presentations will be available on Allakos' website post-event.
On May 11, 2020, Allakos (Nasdaq: ALLK) announced acceptance of an oral presentation at the ASCRS Virtual Annual Meeting, scheduled for May 16, 2020, at 6:00 pm ET. The presentation will focus on a Phase 1b study of antolimab (AK002) in patients with severe allergic conjunctivitis. This study evaluated the drug's effectiveness against three forms of the condition resistant to topical treatments. Following the presentation, slides will be made available on Allakos' website.
Summary not available.